Alnylam Pharmaceuticals · 23 hours ago
Principal Scientist, Advanced In Vitro Platforms
Cambridge, MA
Full-time
Onsite
Senior Level, Lead/Staff
$143K/yr - $214K/yr
6+ years expAlnylam Pharmaceuticals is seeking an accomplished and motivated Principal Scientist to lead innovation in advanced in vitro modeling for RNAi discovery and development. The role involves designing, validating, and implementing model systems to enhance biological predictivity and increase translational confidence across multiple therapeutic areas.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Hiring Manager
Jeannine Ripley
Responsibilities
Lead and mentor the Advanced In Vitro Delivery group, fostering scientific excellence and ensuring the team remains at the forefront of emerging technologies and methodologies
Shape scientific strategy by staying current with advances in RNAi therapeutics and contributing to the strategic direction of discovery and platform development efforts
Collaborate cross-functionally with internal teams and CRO partners to develop, validate, and implement advanced in vitro systems—including 2D, 3D, organoid, and organ-on-a-chip models—that are predictive of in vivo siRNA uptake and biological activity
Drive experimental execution, including design, implementation, and troubleshooting of complex in vitro studies to evaluate siRNA delivery and mechanism of action
Provide technical leadership in the development and deployment of next-generation in vitro modeling technologies across multiple tissue types
Adapt and miniaturize advanced cell culture systems for automated, high-throughput screening applications
Perform and oversee analytical assays, including imaging, ELISA, Western blotting, and cell-based functional assays, to assess siRNA delivery efficiency and receptor-mediated uptake
Analyze and interpret data, integrating imaging and functional readouts, and effectively communicate results to internal stakeholders and external collaborators
Partner with discovery teams to integrate validated in vitro models into RNAi screening and lead optimization workflows
Qualification
Required
Ph.D. in Cell Biology, Pharmacology, or a related discipline with 6+ years of hands-on industry experience in a biotechnology or pharmaceutical environment
Demonstrated expertise in ex vivo cell assays, microphysiological systems (MPS), primary and iPSC-derived cell culture, and cell-based functional assays
Strong understanding of in vitro assay development and the application of 2D and 3D culture systems to model and predict in vivo siRNA delivery, uptake, and activity
Proven experience with 3D culture platforms, including spheroids, organoids, and co-culture models
Exceptional organizational and analytical skills, with the ability to independently troubleshoot, optimize, and innovate experimental approaches
Effective team collaborator and communicator, capable of presenting scientific findings clearly to diverse audiences
Self-driven and proactive, with the ability to lead projects, manage multiple priorities, and adapt to evolving objectives in a fast-paced environment
Strong project management and leadership skills, with a proven ability to lead teams and deliver results through cross-functional collaboration
Preferred
Experience with oligonucleotide or RNAi-based therapeutics is highly desirable
Benefits
Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
H1B Sponsorship
Alnylam Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2022 (18)
2021 (19)
2020 (7)
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
Longevity.Technology
2026-01-14
2026-01-13
Company data provided by crunchbase